262 related articles for article (PubMed ID: 26803050)
1. Therapeutic drug monitoring in neonates.
Pauwels S; Allegaert K
Arch Dis Child; 2016 Apr; 101(4):377-81. PubMed ID: 26803050
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic modelling and Bayesian estimation-assisted decision tools to optimize vancomycin dosage in neonates: only one piece of the puzzle.
Allegaert K; Flint R; Smits A
Expert Opin Drug Metab Toxicol; 2019 Sep; 15(9):735-749. PubMed ID: 31402708
[No Abstract] [Full Text] [Related]
3. Vancomycin continuous infusion in neonates: dosing optimisation and therapeutic drug monitoring.
Zhao W; Lopez E; Biran V; Durrmeyer X; Fakhoury M; Jacqz-Aigrain E
Arch Dis Child; 2013 Jun; 98(6):449-53. PubMed ID: 23254142
[TBL] [Abstract][Full Text] [Related]
4. Quantitative clinical pharmacology practice for optimal use of antibiotics during the neonatal period.
Samardzic J; Allegaert K; Wilbaux M; Pfister M; van den Anker JN
Expert Opin Drug Metab Toxicol; 2016; 12(4):367-75. PubMed ID: 26817821
[TBL] [Abstract][Full Text] [Related]
5. [Is therapeutic drug monitoring (TDM) in paediatric patients necessary?].
Prokopczyk J; Piekarczyk A; Kaminska E
Med Wieku Rozwoj; 2001; 5(2):149-55. PubMed ID: 11679679
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of vancomycin dosing regimens in preterm and term neonates using Monte Carlo simulations.
Mehrotra N; Tang L; Phelps SJ; Meibohm B
Pharmacotherapy; 2012 May; 32(5):408-19. PubMed ID: 22488303
[TBL] [Abstract][Full Text] [Related]
7. Vancomycin prescription in neonates and young infants: toward a simplified dosage.
Oudin C; Vialet R; Boulamery A; Martin C; Simon N
Arch Dis Child Fetal Neonatal Ed; 2011 Sep; 96(5):F365-70. PubMed ID: 21378399
[TBL] [Abstract][Full Text] [Related]
8. Model-based clinical dose optimization for phenobarbital in neonates: An illustration of the importance of data sharing and external validation.
Völler S; Flint RB; Stolk LM; Degraeuwe PLJ; Simons SHP; Pokorna P; Burger DM; de Groot R; Tibboel D; Knibbe CAJ;
Eur J Pharm Sci; 2017 Nov; 109S():S90-S97. PubMed ID: 28506869
[TBL] [Abstract][Full Text] [Related]
9. Pitfalls in TDM of antibiotic drugs: analytical and modelling issues.
Neef C; Touw DJ; Harteveld AR; Eerland JJ; Uges DR
Ther Drug Monit; 2006 Oct; 28(5):686-9. PubMed ID: 17038886
[TBL] [Abstract][Full Text] [Related]
10. Development of Vancomycin Dose Individualization Strategy by Bayesian Prediction in Patients Receiving Continuous Renal Replacement Therapy.
Oda K; Jono H; Kamohara H; Nishi K; Tanoue N; Saito H
Pharm Res; 2020 May; 37(6):108. PubMed ID: 32468340
[TBL] [Abstract][Full Text] [Related]
11. How to use vancomycin optimally in neonates: remaining questions.
Jacqz-Aigrain E; Leroux S; Zhao W; van den Anker JN; Sharland M
Expert Rev Clin Pharmacol; 2015; 8(5):635-48. PubMed ID: 26289222
[TBL] [Abstract][Full Text] [Related]
12. Variation in gentamicin and vancomycin dosage and monitoring in UK neonatal units.
Kadambari S; Heath PT; Sharland M; Lewis S; Nichols A; Turner MA
J Antimicrob Chemother; 2011 Nov; 66(11):2647-50. PubMed ID: 21862473
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic drug monitoring and pharmacokinetic dose prediction methods.
Oellerich M
Wien Klin Wochenschr Suppl; 1992; 191():12-5. PubMed ID: 1509745
[TBL] [Abstract][Full Text] [Related]
14. Use of Machine Learning for Dosage Individualization of Vancomycin in Neonates.
Tang BH; Zhang JY; Allegaert K; Hao GX; Yao BF; Leroux S; Thomson AH; Yu Z; Gao F; Zheng Y; Zhou Y; Capparelli EV; Biran V; Simon N; Meibohm B; Lo YL; Marques R; Peris JE; Lutsar I; Saito J; Jacqz-Aigrain E; van den Anker J; Wu YE; Zhao W
Clin Pharmacokinet; 2023 Aug; 62(8):1105-1116. PubMed ID: 37300630
[TBL] [Abstract][Full Text] [Related]
15. Neonatal vancomycin continuous infusion: still a confusion?
Gwee A; Cranswick N; Metz D; Coghlan B; Daley AJ; Bryant PA; Curtis N
Pediatr Infect Dis J; 2014 Jun; 33(6):600-5. PubMed ID: 24378952
[TBL] [Abstract][Full Text] [Related]
16. Population pharmacokinetics of phenobarbital by mixed effect modelling using routine clinical pharmacokinetic data in Japanese neonates and infants: an update.
Yukawa M; Yukawa E; Suematsu F; Takiguchi T; Ikeda H; Aki H; Mimemoto M
J Clin Pharm Ther; 2011 Dec; 36(6):704-10. PubMed ID: 22023343
[TBL] [Abstract][Full Text] [Related]
17. [Level of evidence for therapeutic drug monitoring of vancomycin].
Jelassi ML; Benlmouden A; Lefeuvre S; Mainardi JL; Billaud EM;
Therapie; 2011; 66(1):29-37. PubMed ID: 21466775
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetic/pharmacodynamic rationale for administering vancomycin via continuous infusion.
Waineo MF; Kuhn TC; Brown DL
J Clin Pharm Ther; 2015 Jun; 40(3):259-65. PubMed ID: 25865426
[TBL] [Abstract][Full Text] [Related]
19. DosOpt: A Tool for Personalized Bayesian Dose Adjustment of Vancomycin in Neonates.
Tasa T; Metsvaht T; Kalamees R; Vilo J; Lutsar I
Ther Drug Monit; 2017 Dec; 39(6):604-613. PubMed ID: 29084032
[TBL] [Abstract][Full Text] [Related]
20. [Therapeutic monitoring: analytic, pharmacokinetic and clinical aspects].
Marquet P
Acta Clin Belg; 1999; 53 Suppl 1():2-12. PubMed ID: 10216973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
